Replies to post #3317 on Antares Pharma, Inc. (ATRS)

[Birdstone]

I wouldn't put much faith in Ali's numbers if he's saying $100MM in 2015. $55MM total revenues may be conservative. If so, great.

The real increase will come in 2016 and beyond, with Otrexup being on the market for 3 years and gaining share, plus epipen and QST just hitting the market. All ATRS products will require time to ramp up sales as these aren't life-saving drugs that jump off the shelves. Ultimately QST is the biggest hitter in the ATRS pipeline from a revenue potential standpoint. But again, it won't launch until the back half of 2016 or even early 2017.